Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice.

BACKGROUND

The combination of

PATIENTS AND METHODS

Retrospective, observational, cross-sectional, multicenter study involving 41 patients with advanced melanoma harboring a

RESULTS

During the combination therapy, 12 patients (29.3%) had a CR, 19 a PR (46.3%), 5 showed SD (12.2%), and 5 had PD. A total of 12 patients (29.3%) were considered as achieving a durable response and 29 (70.7%) as a non-durable one. Practically all sociodemographic and clinical characteristics were similar between patients. Body mass index was the only differential factor (with higher body mass index achieving a non-durable response). The treatment adherence was 100% in patients with durable response and 66.7% in those with non-durable.

CONCLUSION

The combination treatment with vemurafenib/cobimetinib results in an important impact on long-term survival, leading to a steady CR in one-third of the patients.

Informations de copyright

© 2021 Álamo et al.

Déclaration de conflit d'intérêts

BCB declares that has received consulting honoraria from Boehringer and Sanofi and is on the speaker’s bureau of Roche, Novartis, Merck Sharp & Dohme, Bristol-Myers Squibb, Rovi, Leopharma, Astra Zeneca, Leo-Pharma, and Sanofi. EMC declares that has received consulting honoraria, including travel and accommodation paid, and is on the speaker’s bureau of Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme, Sanofi, Roche and Pierre Fabre. FG declares that has received consulting honoraria from Amgen, Merck Sharp & Dohme, Bristol-Myers Squibb and Roche. GC declares that has received consulting honoraria, including travel and accommodation paid, from Janssen, IPSEN, Novartis, Roche, Pierre Fabre, Bristol-Myers Squibb, Sanofi, and EISAI, and is on the speaker’s bureau of Roche, Merck, EVSA Pharma, EISAI, and Merck Sharp & Dohme. JM declares that has received consulting honoraria, including travel and accommodation paid, from Roche, Bristol-Myers Squibb, and Novartis, and is on the speaker’s bureau of Roche, Bristol-Myers Squibb, Novartis, Merck Sharp & Dohme, and Pierre Fabre. MC declares that received consulting honoraria, including travel and accommodation paid, from Novartis, Roche, Pierre Fabre, and Merck Sharp & Dohme. SO declares that has received consulting honoraria from Roche, Novartis, Merck Sharp & Dohme, and Bristol-Myers Squibb. The authors report no other conflicts of interest in this work.